These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 7545749)

  • 1. [Conformational analysis of peptide antagonists in the design of pseudopeptide and non-peptide antagonists].
    Goldstein S; Neuwels M; Lassoie MA; Houssin R; Caumont K; Differding E; Henichart JP
    J Pharm Belg; 1995; 50(2-3):213-22. PubMed ID: 7545749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic pentapeptides of chiral sequence DLDDL as scaffold for antagonism of G-protein coupled receptors: synthesis, activity and conformational analysis by NMR and molecular dynamics of ITF 1565 a substance P inhibitor.
    Porcelli M; Casu M; Lai A; Saba G; Pinori M; Cappelletti S; Mascagni P
    Biopolymers; 1999 Aug; 50(2):211-9. PubMed ID: 10380345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane-induced secondary structures of neuropeptides: a comparison of the solution conformations adopted by agonists and antagonists of the mammalian tachykinin NK1 receptor.
    Whitehead TL; McNair SD; Hadden CE; Young JK; Hicks RP
    J Med Chem; 1998 Apr; 41(9):1497-506. PubMed ID: 9554882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptors and antagonists for substance P and related peptides.
    Regoli D; Boudon A; Fauchére JL
    Pharmacol Rev; 1994 Dec; 46(4):551-99. PubMed ID: 7534932
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
    Patacchini R; Quartara L; Astolfi M; Goso C; Giachetti A; Maggi CA
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1082-7. PubMed ID: 7891319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurokinin-1 receptor antagonists: a comprehensive patent survey.
    Huang SC; Korlipara VL
    Expert Opin Ther Pat; 2010 Aug; 20(8):1019-45. PubMed ID: 20533894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel NK-1 tachykinin receptor antagonists: the use of cycloalkyl amino acids as a template.
    Sisto A; Bonelli F; Centini F; Fincham CI; Potier E; Monteagudo E; Lombardi P; Arcamone F; Goso C; Manzini S
    Biopolymers; 1995 Oct; 36(4):511-24. PubMed ID: 7578945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic targets for neurokinin-1 receptor antagonists.
    Duffy RA
    Expert Opin Emerg Drugs; 2004 May; 9(1):9-21. PubMed ID: 15155133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptide antagonists of the NK1 tachykinin receptor.
    McLean S
    Med Res Rev; 1996 Jul; 16(4):297-317. PubMed ID: 8798177
    [No Abstract]   [Full Text] [Related]  

  • 10. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
    Ciucci A; Palma C; Manzini S; Werge TM
    Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A turning point in the knowledge of the structure-function-activity relations of elastin].
    Alix AJ
    J Soc Biol; 2001; 195(2):181-93. PubMed ID: 11727705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of various proposed models of the receptor-bound conformation of H-Tyr-Tic-Phe-OH related delta-opioid antagonists.
    Wilkes BC; Schiller PW
    Biopolymers; 1995; 37(6):391-400. PubMed ID: 8589244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists.
    Ohnmacht CJ; Albert JS; Bernstein PR; Rumsey WL; Masek BB; Dembofsky BT; Koether GM; Andisik DW; Aharony D
    Bioorg Med Chem; 2004 May; 12(10):2653-69. PubMed ID: 15110847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of potent peptide agonists and antagonists for the endothelin receptors.
    Cody WL; Doherty AM
    Biopolymers; 1995; 37(2):89-104. PubMed ID: 7893949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor.
    Takeuchi Y; Shands EF; Beusen DD; Marshall GR
    J Med Chem; 1998 Sep; 41(19):3609-23. PubMed ID: 9733486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.
    Hirschmann R; Yao W; Cascieri MA; Strader CD; Maechler L; Cichy-Knight MA; Hynes J; van Rijn RD; Sprengeler PA; Smith AB
    J Med Chem; 1996 Jun; 39(13):2441-8. PubMed ID: 8691440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.
    Rupniak NM
    Curr Opin Investig Drugs; 2002 Feb; 3(2):257-61. PubMed ID: 12020057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
    Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D
    Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components.
    Seebach D; Beck AK; Bierbaum DJ
    Chem Biodivers; 2004 Aug; 1(8):1111-239. PubMed ID: 17191902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the N-terminal and mid-region residues of substance P in regulating functional selectivity at the tachykinin NK1 receptor.
    Perrine SA; Beard DJ; Young JK; Simmons MA
    Eur J Pharmacol; 2008 Sep; 592(1-3):1-6. PubMed ID: 18634782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.